The content on this page is designed for Australia. Check courses designed for Canada (EN)

This course has expired. View available courses.

Medication Management, Women's Health

Novel treatment paradigms for oral contraception

The oral contraceptive pill (OCP) is the most commonly used method of contraception and may also be prescribed for a range of other indications.

The combined oral contraceptive pill (COCP), containing both oestrogen and progestogen is highly effective but may be associated with a range of adverse effects. The traditional progestogen only pill (POP) is generally associated with fewer adverse effects but the window of opportunity for taking a missed pill is shorter than for the COCP (3 hour versus 24 hours). The new POP formulation, drospirenone, has a 24 hour window for taking a missed pill and has shown efficacy while being associated with minimal adverse effects.

Most women in Australia access contraception via their GPs. As such, GPs have an important role to play in providing patients with information about the available contraceptive options, while individualising prescriptions appropriately and providing guidance to optimise OCP efficacy.


This educational activity was developed by MDBriefCase at the request, and with funding from Besins.

DURATION

1 hr

PROFESSION

Physician

# OF CREDITS

2

ACCREDITATION

RACGP CPD Program

EXPIRY DATE

2022-12-31

The oral contraceptive pill (OCP) is the most commonly used method of contraception and may also be prescribed for a range of other indications.

The combined oral contraceptive pill (COCP), containing both oestrogen and progestogen is highly effective but may be associated with a range of adverse effects. The traditional progestogen only pill (POP) is generally associated with fewer adverse effects but the window of opportunity for taking a missed pill is shorter than for the COCP (3 hour versus 24 hours). The new POP formulation, drospirenone, has a 24 hour window for taking a missed pill and has shown efficacy while being associated with minimal adverse effects.

Most women in Australia access contraception via their GPs. As such, GPs have an important role to play in providing patients with information about the available contraceptive options, while individualising prescriptions appropriately and providing guidance to optimise OCP efficacy.


This educational activity was developed by MDBriefCase at the request, and with funding from Besins.

Faculty

Professor Rodney Baber AM
Professor of Obstetrics and Gynaecology (USYD)
Sydney, New South Wales

Dr Therese Foran
Sexual Health Physician
Sydney, New South Wales

Learning objectives

Upon completion of this continuing education program participants will be better able to:

  • Describe the mechanism of action of different oral hormonal contraceptive agents
  • Outline the differences between the combined oral contraceptive pill (COCP) and the progestogen only pill (POP)
  • Identify patients for whom a POP would be appropriate
  • Review the options within the class of POP contraceptives
  • Counsel patients about contraindications and risk profiles of different oral hormonal contraceptives

Accreditation

This Active Learning Module has been approved by RACGP CPD Program for 2 CPD points.

Activity no. 315257

Cost of course:  
Free
# of credits: 2
Duration: 1 hr

FAQs & HELP

MDBriefCase Group specializes in accredited, online continuing professional development (CPD) programs, custom tailored for specific international markets and available on a convenient online platform.

All content is developed by leading specialists and peer-reviewed by experts at respected institutions, which keeps more than 280,000 global healthcare professionals at the forefront of the latest evidence and protocols worldwide.

The vast majority of our programs are accredited by one or more respected institutions. We do provide unaccredited content to ensure that healthcare professionals have access to relevant practical resources in addition to accredited learning.

Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.

MDBriefCase Group works with various institutions to provide peer-reviewed, up-to-date accredited content. Our programs and resources are provided via collaboration between medical writers, faculty members, associations, universities and other relevant organizations. The content you were recommended is likely valued by your society or association and is conveniently provided to you free of charge on an MDBriefCase Group platform.

Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.

No, registration with MDBriefCase is free!

To access your profile, visit My Profile. If you would like to update the information here don’t forget to hit the ‘save’ button when you are finished. Your profile is where you can control what email communications you receive.

If you have forgotten your password, you can reset your password. To access this page from the Login page, click Forgot password. Enter the email address you registered with and you will receive an email with a link to reset your password.

Please note: if you submitted multiple password resets, only the link on the most recent email is valid.

You can unsubscribe from MDBriefCase Group emails by clicking the unsubscribe button located at the bottom of each of our emails.

Novel treatment paradigms for oral contraception

1 hr

Duration

Physician

Profession

2

# of credits

Learning Objectives

Upon completion of this continuing education program participants will be better able to:

  • Describe the mechanism of action of different oral hormonal contraceptive agents
  • Outline the differences between the combined oral contraceptive pill (COCP) and the progestogen only pill (POP)
  • Identify patients for whom a POP would be appropriate
  • Review the options within the class of POP contraceptives
  • Counsel patients about contraindications and risk profiles of different oral hormonal contraceptives

RACGP CPD Program

ACCREDITATION

Medication Management, Women's Health

Learning Category

Medication

Topic

0

Price

2022-12-31

Expiry Date

AUS

Region/Language

Course Description

The oral contraceptive pill (OCP) is the most commonly used method of contraception and may also be prescribed for a range of other indications.

The combined oral contraceptive pill (COCP), containing both oestrogen and progestogen is highly effective but may be associated with a range of adverse effects. The traditional progestogen only pill (POP) is generally associated with fewer adverse effects but the window of opportunity for taking a missed pill is shorter than for the COCP (3 hour versus 24 hours). The new POP formulation, drospirenone, has a 24 hour window for taking a missed pill and has shown efficacy while being associated with minimal adverse effects.

Most women in Australia access contraception via their GPs. As such, GPs have an important role to play in providing patients with information about the available contraceptive options, while individualising prescriptions appropriately and providing guidance to optimise OCP efficacy.


This educational activity was developed by MDBriefCase at the request, and with funding from Besins.

Faculty

Professor Rodney Baber AM
Professor of Obstetrics and Gynaecology (USYD)
Sydney, New South Wales

Dr Therese Foran
Sexual Health Physician
Sydney, New South Wales

Accreditation

This Active Learning Module has been approved by RACGP CPD Program for 2 CPD points.

Activity no. 315257